Mirati Therapeutics (MRTX) Tops Q2 EPS by 13c, beats revenue

Mirati Therapeutics (NASDAQ: MRTX) reported Q2 EPS of ($3.04), $0.13 better than the analyst estimate of ($3.17). Revenue for the quarter came in at $13.69 million versus the consensus estimate of $13.19 million.

For earnings history and earnings-related data on Mirati Therapeutics (MRTX) click here.

You May Also Be Interested In

• U.S. economy adds 199,000 jobs in November
• Analysts defend Broadcom as annual guidance falls short after FQ4 earnings beat
• Broadcom (AVGO) Tops Q4 EPS by 10c, Offers Guidance